23:45 , Jun 19, 2019 |  BC Extra  |  Clinical News

June 19 Clinical Quick Takes: G1 jumps on breast cancer data; plus Linzess, Lokelma, Boehringer/OSE, GCAR and more

G1 rises on trilaciclib OS efficacy in Phase II for TNBC  G1 Therapeutics Inc. (NASDAQ:GTHX) has gained 33% to $26.27 since reporting preliminary data Tuesday from a Phase II trial showing a statistically significant improvement...
00:04 , Apr 6, 2019 |  BioCentury  |  Finance

Everybody up

Biotech stocks were off to a strong start in 1Q19, with 71% of companies tracked by BioCentury seeing market cap growth in the quarter. Across all market cap bands, biotechs saw a median gain of...
20:04 , Jan 18, 2019 |  BC Week In Review  |  Clinical News

China approves Linzess for IBS-C

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) said China's National Medical Products Administration approved Linzess linaclotide to treat irritable bowel syndrome with constipation (IBS-C). The company expects to launch the guanylate cyclase C (GCC; GUCY2C) agonist in China...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
23:55 , Jan 2, 2019 |  BC Extra  |  Politics & Policy

Part D beneficiaries hit hardest under 2019 price hikes

Drug price increases announced beginning Jan. 1 will disproportionately affect Medicare Part D beneficiaries, reinforcing a practice the Trump administration has sought to curb. Data from Evercore ISI Research on 13 pharmaceutical and biotech companies...
19:58 , Nov 2, 2018 |  BC Week In Review  |  Company News

Linzess growth figures disappoint investors

Allergan plc (NYSE:AGN) said it expects future growth for Linzess linaclotide to be in the low- to mid-single digits, sending shares of partner Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) down $2.91 (18%) to $13.18 on Oct. 30....
21:57 , Oct 30, 2018 |  BC Extra  |  Company News

Linzess growth figures disappoint investors

Allergan plc (NYSE:AGN) said it expects future growth for Linzess linaclotide to be in the low- to mid-single digits, sending shares of partner Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) down $2.91 (18%) to $13.18. Allergan, which relayed...
00:08 , Jul 21, 2018 |  BioCentury  |  Product Development

Getting to the point in IBS

A large epidemiological study set Ironwood Pharmaceuticals Inc. on a path to finding symptomatic outcomes important to IBS-C patients. The company’s new Phase IIIb study of Linzess linaclotide will probe those outcomes, seeking results that...
16:13 , Jul 20, 2018 |  BC Week In Review  |  Clinical News

Ironwood, Allergan start Phase IIIb of Linzess in IBS-C

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) and Allergan plc (NYSE:AGN) began a double-blind, placebo-controlled, U.S. Phase IIIb trial to evaluate 290 µg Linzess linaclotide once daily in about 600 patients with irritable bowel syndrome with constipation (IBS-C)....
19:02 , May 25, 2018 |  BC Week In Review  |  Company News

Astellas unveils new R&D strategy

Astellas Pharma Inc. (Tokyo:4503) President and CEO Kenji Yasukawa, who took the reins in April, unveiled his 2018 strategic plan for the company May 22, including a shift in R&D focus and restructuring of Japan...